This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

What it means for patients - The compounded versions of the drug were originally sold to combat a brand-name shortage ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

(NASDAQ:MTVA) announced positive results from the Phase 1 Part 2 multiple ascending dose (MAD) trial of DA-1726 in obesity.

The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients ... But leading treatments like Zepbound and Novo Nordisk’s Wegovy are ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...

This article looks at how long you can take Wegovy for weight loss, what results you might have, and what happens if you stop using it. No. The recommended starting dose for Wegovy is 0.25 ...

CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Semaglutide is available as Wegovy and Ozempic injections, and also as Rybelsus tablets. The study's findings indicate a potential link between these medications and a lower risk of dementia.